Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.




Bladder cancer is the most common malignancy in the urinary system. The American Cancer Society estimates that in 2019, the U.S. will see about 80,470 new cases of bladder cancer (approximately 61,700 in men and 18,770 in women). Urothelial carcinoma accounts for 90 percent of bladder cancers. Until recently, patients with advanced disease faced limited treatment options that generally yielded poor outcomes.

With the addition of checkpoint inhibitor immunotherapy to the treatment armamentarium for advanced bladder cancer, the care landscape for urothelial carcinoma is evolving. Keeping abreast of emerging clinical efficacy data, evidence-based practice guidelines, effective practices for monitoring and managing immune-related adverse events, and optimal approaches for 
patient education on treatment options for advanced bladder cancer.

The ACCC education program on Optimizing Outcomes for Urothelial Carcinoma in the Community Setting is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapy and other novel targeted therapies into the treatment of advanced urothelial carcinoma.

The program will be presented in two formats: a live, on-site learning workshop and as an audio-guided web course. 

Live Workshops

At the live workshops, a three-member multidisciplinary expert faculty panel will provide both didactic presentations and collaborative open discussion with members of the multidisciplinary care team. Topics covered include, but are not limited to, a review of current evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors, patient selection criteria, and monitoring and managing immune-related adverse events (irAEs) in patients with advanced urothelial carcinoma. Collateral issues discussed include coordination and communication within the multidisciplinary care team, coverage and reimbursement, and fostering patient education and engagement.

During the workshop, participants will use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan. Workshop sites will report on their progress post-participation.

If your program is interested in hosting this education program, please contact Mary Stanley, Program Manager, ACCC Provider Education.

Continuing Education Credit available:

  • Learning Workshops (CME/CNE/MOC credit provided – no CPE) – 4 credit hours
  • Audio-guided Web Course (CME/CNE provided – no CPE, no MOC) – 1 credit hour

Online Course

This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with new and emerging therapies in the community setting and strategies to engage patients in the shared decision-making process. This initiative will review the mechanism of action for immunotherapies and emerging targeted therapies, summarize recent clinical data for these therapies, and examine best practices for the management of advanced and metastatic urothelial carcinoma.


Jointly Provided By:

AXIS Medical Education Logo


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Astellas, and Seattle Genetics, Inc.